Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
HER2 / pan-EGFR TKI
Neratinib
Nerlynx · NER
Irreversible pan-HER/EGFR TKI whose severe diarrhea is the renal villain — dehydration drives prerenal AKI, mitigated by loperamide prophylaxis.
ModerateIrreversible pan-HER TKI era · approved 2017
Extended adjuvant therapy of early-stage HER2-positive breast cancer after trastuzumabAdvanced/metastatic HER2-positive breast cancer (with capecitabine)
Signature kidney injury
Prerenal / Hemodynamic AKI
Diarrhea is near-universal without prophylaxis: in ExteNET, grade 3 diarrhea occurred in ~40% without antidiarrheal prophylaxis, falling substantially with loperamide and dose-escalation strategies (CONTROL). The resulting volume-depletion prerenal AKI is not separately quantified.
Source: Chan et al., Lancet Oncol 2016 (ExteNET); Barcenas et al., Ann Oncol 2020 (CONTROL)
Mechanism of kidney injury
Pan-HER/EGFR inhibition disrupts EGFR-dependent chloride and fluid handling in the intestinal epithelium, producing secretory diarrhea (a class effect of EGFR-pathway inhibitors). Profuse early diarrhea causes extracellular volume depletion, sodium/potassium/magnesium losses and prerenal azotemia; severe sustained hypovolemia can progress to ischemic ATN. The kidney injury is hemodynamic/electrolyte-mediated, not a direct neratinib nephrotoxicity.
Clinical presentation
Early-onset (often first cycle), high-volume watery diarrhea, dehydration, orthostasis and electrolyte loss (hypokalemia, hypomagnesemia); creatinine rises with a low FeNa and concentrated urine typical of prerenal physiology.
Onset
Diarrhea characteristically within the first days-to-weeks; prerenal AKI follows uncontrolled fluid loss.
Reversibility
Reversible
Anticancer mechanism
Oral irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that covalently binds the kinase cysteine residue, providing sustained pan-HER blockade. Used as extended adjuvant therapy after trastuzumab in HER2-positive breast cancer and in metastatic disease.
Management
Aggressive antidiarrheal therapy (loperamide, adding budesonide/colestipol per CONTROL), oral/IV rehydration and electrolyte correction; hold or reduce neratinib for severe diarrhea. Restore volume to reverse prerenal AKI; persistent injury despite euvolemia should prompt evaluation for ATN. Prophylaxis is the key preventive measure.
Risk factors
- Absence of antidiarrheal prophylaxis
- Pre-existing CKD, diuretic use or baseline volume depletion
- Concurrent capecitabine (additive GI toxicity)
- Older age and frailty
Prevention
- Loperamide prophylaxis from day 1 (and/or dose-escalation of neratinib per CONTROL)
- Patient education on early antidiarrheal use and hydration
- Electrolyte monitoring and repletion (potassium, magnesium)
- Dose interruption/reduction for grade 3+ diarrhea
Note · The renal link is indirect: neratinib causes severe secretory diarrhea, and AKI arises from dehydration/electrolyte loss rather than a direct renal lesion. No neratinib-specific AKI paper exists; diarrhea-prophylaxis trials carry the signal.
Clinical depth
Renal dose adjustment
No dose adjustment for mild-moderate renal impairment; severe impairment/ESKD not well studied (hepatic CYP3A4 metabolism). Dose changes are driven by diarrhea and hepatotoxicity.
Dialyzability & ESKD dosing
Highly protein-bound; not expected to be dialyzable. No established ESKD dosing.
Differential diagnosis
Distinguish prerenal AKI from diarrhea (volume-responsive, low FeNa) from infectious diarrhea, capecitabine-related GI toxicity, and intrinsic ATN if hypoperfusion is prolonged. The first-cycle, high-volume secretory pattern is characteristic.
Monitoring
- Stool frequency and volume; weight and volume status, especially in the first cycle
- Serum creatinine, potassium and magnesium during diarrheal episodes
- LFTs periodically (hepatotoxicity)
- Adherence to loperamide prophylaxis
Key trials & series
- ExteNET (Chan, Lancet Oncol 2016) — registrational extended-adjuvant trial defining the grade 3 diarrhea signal
- CONTROL (Barcenas, Ann Oncol 2020) — antidiarrheal prophylaxis/dose-escalation reducing diarrhea
Clinical pearls
- Diarrhea is the dominant, dose-limiting toxicity — loperamide prophylaxis from day 1 transforms tolerability.
- The kidney injury is volume- and electrolyte-mediated; rehydration and magnesium/potassium repletion are central.
- CONTROL-style dose-escalation reduces the diarrhea burden as effectively as antidiarrheals.
- Watch magnesium and potassium — losses are easy to miss and compound the AKI.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Distal Tubule / Collecting Duct
Fine-tuning of Na, K, Mg, acid & water
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of her2 / pan-egfr tkis.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Acneiform rash, paronychia
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Interstitial lung disease (EGFR TKIs)
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkNeratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Chan A et al. · Lancet Oncol 2016 · PMID 26874901Registrational trial defining the grade 3 diarrhea (~40%) that drives prerenal injury.PMIDImproving tolerability of neratinib: the CONTROL trial of antidiarrheal prophylaxis and dose-escalation strategies.Barcenas CH et al. · Ann Oncol 2020 · PMID 32464281Prophylaxis/dose-escalation strategies substantially reducing the diarrhea that causes dehydration.PMIDFinal analysis of the CONTROL trial of neratinib diarrhea-management strategies.Chan A et al. · Breast 2022 · PMID 36702070Final CONTROL data confirming durable diarrhea reduction.PMIDNeratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis.Martin M et al. · Lancet Oncol 2017 · PMID 29146401Long-term efficacy/safety confirming the persistent GI toxicity profile.PMIDDiarrhea associated with HER2-targeted tyrosine kinase inhibitors: mechanisms and management.Rugo HS et al. · Oncologist 2019 · PMID 30671765Mechanism of EGFR/HER-pathway secretory diarrhea underlying the volume loss.PMIDNeratinib: First Global Approval.Deeks ED et al. · Drugs 2017 · PMID 28884417Approval profile summarizing pharmacology and the diarrhea-dominant safety profile.
Related agents
Other agents sharing the same signature kidney injury.